The effect of pulmonary artery catheter use on costs and Long-Term outcomes of acute lung injury

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Clermont, Gilles ^a   Kong, Lan ^a,b   Weissfeld, Lisa A ^a,b   Lave, Judith R ^c   Rubenfeld, Gordon D ^d   Roberts, Mark S ^a,c   Connors, Alfred F ^e   Bernard, Gordon R ^f   Thompson, B Taylor ^g   Wheeler, Arthur P ^f   Angus, Derek C ^a,b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VANDERBILT UNIVERSITY   (United States)

^g HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LUNG INJURY; ADULT; ARTICLE; CENTRAL VENOUS CATHETER; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; MORTALITY; PULMONARY ARTERY CATHETER; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; SURVIVOR; CENTRAL VENOUS CATHETERIZATION; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; ECONOMICS; HOSPITAL DISCHARGE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; SENSITIVITY AND SPECIFICITY; SWAN GANZ CATHETER; TIME; TREATMENT OUTCOME;

ACUTE LUNG INJURY; CATHETERIZATION, CENTRAL VENOUS; CATHETERIZATION, SWAN-GANZ; COHORT STUDIES; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MONTE CARLO METHOD; PATIENT DISCHARGE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960619692     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022512     Document Type: Article

References (24)

1. Wheeler AP, Bernard GR, Thompson BT, Schoenfeld D, Wiedemann HP, et al. (2006) Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 354: 2213-2224.
2. Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, et al. (2005) Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. Lancet 366: 472-477.
3. Richard C, Warszawski J, Anguel N, Deye N, Combes A, et al. (2003) Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial. JAMA 290: 2713-2720.
4. Sandham JD, Hull RD, Brant RF, Knox L, Pineo GF, et al. (2003) A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 348: 5-14.
5. Wiener RS, Welch HG, (2007) Trends in the use of the pulmonary artery catheter in the United States, 1993-2004. JAMA 298: 423-429.
6. Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, et al. (2003) One-year outcomes in survivors of the acute respiratory distress syndrome. NEJM 348: 683-693.
7. Cheung AM, Tansey CM, Tomlinson G, Diaz-Granados N, Matte A, et al. (2006) Two-year outcomes, health care use, and costs of survivors of acute respiratory distress syndrome. Am J Respir Crit Care Med 174: 538-544.
8. Angus DC, Clermont G, Linde-Zwirble WT, Musthafa AA, Dremsizov TT, et al. (2006) Healthcare costs and long-term outcomes after acute respiratory distress syndrome: A phase III trial of inhaled nitric oxide*. Crit Care Med [October 23 Epub ahead of print].
9. Herridge MS, Angus DC, (2005) Acute lung injury--affecting many lives. N Engl J Med 353: 1736-1738.
10. Angus DC, Rubenfeld GD, Roberts MS, Curtis JR, Connors AF, et al. (2002) Understanding costs and cost-effectiveness in critical care: report from the second American Thoracic Society workshop on outcomes research. Am J Respir Crit Care Med 165: 540-550.
11. Feeny D, Furlong W, Boyle M, Torrance GW, (1995) Multi-attribute health status classification systems. Health Utilities Index. PharmacoEconomics 7: 490-502.
12. Rothman ML, Hedrick SC, Bulcroft KA, Hickam DH, Rubenstein LZ, (1991) The validity of proxy-generated scores as measures of patient health status. Med Care 29: 115-124.
13. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC, (1996) The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 276: 1172-1177.
14. Angus DC, Musthafa AA, Clermont G, Griffin MF, Linde-Zwirble WT, et al. (2001) Quality-adjusted survival in the first year after the acute respiratory distress syndrome. Am J Respir Crit Care Med 163: 1389-1394.
15. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB, for the Panel on Cost-Effectiveness in Health and Medicine (1996) Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 276: 1253-1258.
16. Laupacis A, Feeny D, Detsky AS, Tugwell PX, (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 146: 473-481.
17. Rubenfeld GD, Herridge MS, (2007) Epidemiology and outcomes of acute lung injury. Chest 131: 554-562.
18. Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, et al. (2005) Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. Lancet 366: 472-477.
19. Hindorff LA, Rice KM, Lange LA, Diehr P, Halder I, et al. (2008) Common variants in the CRP gene in relation to longevity and cause-specific mortality in older adults: the Cardiovascular Health Study. Atherosclerosis 197: 922-930.
20. Yende S, D'angelo G, Kellum JA, Weissfeld L, Fine J, et al. (2008) Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 177: 1242-1247.
21. Reade MC, Yende S, D'angelo G, Kong L, Kellum JA, et al. (2009) Differences in immune response may explain lower survival among older men with pneumonia. Crit Care Med 37: 1655-1662.
22. Skolarus LE, Sanchez BN, Morgenstern LB, Garcia NM, Smith MA, et al. (2010) Validity of Proxies and Correction for Proxy Use When Evaluating Social Determinants of Health in Stroke Patients. Stroke.
23. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS, (2008) What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 46: 349-356.
24. Angus D, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, et al. (2003) Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 31: 1-11.